VC-backed Arcus Biosciences goes public
Hayward, California-based Arcus Biosciences, a developer of cancer immunotherapies, has raised $120 million for its IPO after pricing its 8 million shares at $15 per share. The stock began trading March 15, 2018 on the New York Stock Exchange under the ticker symbol "RCUS." Citigroup, Goldman Sachs and Leerink Partners are the lead underwriters. The investors included Taiho Ventures, GV, Invus, DROIA Oncology Ventures, Stanford University, The Column Group, Foresite Capital, Novartis and Celgene.
15 March 2018•3 mins read
